{"data":[{"accessionNo":"0001104659-26-097073","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":"55083R203","securityClass":"Common Stock, par value $0.0001","eventDate":"2026-06-30","reportingPerson":"James B. Tananbaum","reportingCik":null,"personType":"IN","sharesOwned":653328,"percentOfClass":2.7,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001104659-26-097073","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":"55083R203","securityClass":"Common Stock, par value $0.0001","eventDate":"2026-06-30","reportingPerson":"Foresite Capital Fund V, L.P.","reportingCik":null,"personType":"PN","sharesOwned":476386,"percentOfClass":1.9,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001104659-26-097073","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":"55083R203","securityClass":"Common Stock, par value $0.0001","eventDate":"2026-06-30","reportingPerson":"Foresite Capital Management V, LLC","reportingCik":null,"personType":"OO","sharesOwned":476386,"percentOfClass":1.9,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001104659-26-097073","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":"55083R203","securityClass":"Common Stock, par value $0.0001","eventDate":"2026-06-30","reportingPerson":"Foresite Capital Opportunity Fund V, L.P.","reportingCik":null,"personType":"PN","sharesOwned":176942,"percentOfClass":0.7,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001104659-26-097073","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":"55083R203","securityClass":"Common Stock, par value $0.0001","eventDate":"2026-06-30","reportingPerson":"Foresite Capital Opportunity Management V, LLC","reportingCik":null,"personType":"OO","sharesOwned":176942,"percentOfClass":0.7,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001104659-26-097073","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":"55083R203","securityClass":"Common Stock, par value $0.0001","eventDate":"2026-06-30","reportingPerson":"Foresite Capital Fund IV, L.P.","reportingCik":null,"personType":"PN","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001104659-26-097073","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":"55083R203","securityClass":"Common Stock, par value $0.0001","eventDate":"2026-06-30","reportingPerson":"Foresite Capital Management IV, LLC","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001140361-26-025769","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":"55083R203","securityClass":"Common Stock, par value $0.0001","eventDate":"2026-05-18","reportingPerson":"Innovative Cellular Therapeutics Holdings Limited","reportingCik":null,"personType":"OO","sharesOwned":3000000,"percentOfClass":12.3,"filedAt":"2026-06-18","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001012975-26-000439","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":"55083R203","securityClass":"Common Stock par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"ARCH Venture Partners IX, LLC","reportingCik":null,"personType":"OO","sharesOwned":3247162,"percentOfClass":13.9,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001012975-26-000439","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":"55083R203","securityClass":"Common Stock par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"ARCH Venture Partners IX Overage, L.P.","reportingCik":null,"personType":"PN","sharesOwned":3247162,"percentOfClass":13.9,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001012975-26-000439","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":"55083R203","securityClass":"Common Stock par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"ARCH Venture Partners IX, L.P.","reportingCik":null,"personType":"PN","sharesOwned":3247162,"percentOfClass":13.9,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001012975-26-000439","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":"55083R203","securityClass":"Common Stock par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"ARCH Venture Fund IX Overage, L.P.","reportingCik":null,"personType":"PN","sharesOwned":3247162,"percentOfClass":13.9,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001012975-26-000439","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":"55083R203","securityClass":"Common Stock par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"ARCH Venture Fund XIII, L.P.","reportingCik":null,"personType":"PN","sharesOwned":3247162,"percentOfClass":13.9,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001012975-26-000439","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":"55083R203","securityClass":"Common Stock par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"ARCH Venture Fund IX, L.P.","reportingCik":null,"personType":"PN","sharesOwned":3247162,"percentOfClass":13.9,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001012975-26-000439","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":"55083R203","securityClass":"Common Stock par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Steven Gillis","reportingCik":null,"personType":"IN","sharesOwned":3247162,"percentOfClass":13.9,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001012975-26-000439","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":"55083R203","securityClass":"Common Stock par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Kristina Burow","reportingCik":null,"personType":"IN","sharesOwned":3247162,"percentOfClass":13.9,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001012975-26-000439","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":"55083R203","securityClass":"Common Stock par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Robert Nelsen","reportingCik":null,"personType":"IN","sharesOwned":3247162,"percentOfClass":13.9,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001012975-26-000439","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":"55083R203","securityClass":"Common Stock par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Keith Crandell","reportingCik":null,"personType":"IN","sharesOwned":3247162,"percentOfClass":13.9,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001012975-26-000439","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":"55083R203","securityClass":"Common Stock par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"ARCH Venture Partners XIII, LLC","reportingCik":null,"personType":"OO","sharesOwned":3247162,"percentOfClass":13.9,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001012975-26-000439","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":"55083R203","securityClass":"Common Stock par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"ARCH Venture Partners XIII, L.P.","reportingCik":null,"personType":"PN","sharesOwned":3247162,"percentOfClass":13.9,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001012975-26-000439","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":"55083R203","securityClass":"Common Stock par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Clinton Bybee","reportingCik":null,"personType":"IN","sharesOwned":1820634,"percentOfClass":7.8,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001012975-26-000439","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":"55083R203","securityClass":"Common Stock par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Paul Berns","reportingCik":null,"personType":"IN","sharesOwned":1426528,"percentOfClass":6.1,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001193125-26-216076","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001806952","issuerName":"LYELL IMMUNOPHARMA, INC.","ticker":"LYEL","cusip":"55083R203","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-31","reportingPerson":"Milky Way Investments Group Ltd.","reportingCik":null,"personType":"CO","sharesOwned":1008116,"percentOfClass":4.3,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001193125-26-216076","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001806952","issuerName":"LYELL IMMUNOPHARMA, INC.","ticker":"LYEL","cusip":"55083R203","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-31","reportingPerson":"MWG Caph Ltd","reportingCik":null,"personType":"CO","sharesOwned":1008116,"percentOfClass":4.3,"filedAt":"2026-05-11","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001168404-26-000021","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":"55083R203","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Explore Investments LLC","reportingCik":null,"personType":"OO","sharesOwned":1529054,"percentOfClass":6.6,"filedAt":"2026-05-08","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001168404-26-000021","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":"55083R203","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Jeffrey P. Bezos","reportingCik":null,"personType":"IN","sharesOwned":1529054,"percentOfClass":6.6,"filedAt":"2026-05-08","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001193125-26-165277","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":"55083R203","securityClass":"Common Stock","eventDate":"2026-03-06","reportingPerson":"EULER FUND, L.P.","reportingCik":null,"personType":"PN","sharesOwned":1426528,"percentOfClass":6.71,"filedAt":"2026-04-21","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001193125-26-165277","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":"55083R203","securityClass":"Common Stock","eventDate":"2026-03-06","reportingPerson":"Antonis Indianos","reportingCik":null,"personType":"IN","sharesOwned":1426528,"percentOfClass":6.71,"filedAt":"2026-04-21","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001193125-26-165277","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":"55083R203","securityClass":"Common Stock","eventDate":"2026-03-06","reportingPerson":"Euler Managers Limited","reportingCik":null,"personType":"CO","sharesOwned":1426528,"percentOfClass":6.71,"filedAt":"2026-04-21","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001012975-25-000768","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":null,"securityClass":"Common Stock par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"ARCH Venture Fund XIII, L.P.","reportingCik":null,"personType":"PN","sharesOwned":2759072,"percentOfClass":13,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001012975-25-000768","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":null,"securityClass":"Common Stock par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"ARCH Venture Partners IX, L.P.","reportingCik":null,"personType":"PN","sharesOwned":2759072,"percentOfClass":13,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001012975-25-000768","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":null,"securityClass":"Common Stock par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"ARCH Venture Partners IX Overage, L.P.","reportingCik":null,"personType":"PN","sharesOwned":2759072,"percentOfClass":13,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001012975-25-000768","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":null,"securityClass":"Common Stock par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"ARCH Venture Partners IX, LLC","reportingCik":null,"personType":"OO","sharesOwned":2759072,"percentOfClass":13,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001012975-25-000768","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":null,"securityClass":"Common Stock par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"ARCH Venture Partners XIII, L.P.","reportingCik":null,"personType":"PN","sharesOwned":2759072,"percentOfClass":13,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001012975-25-000768","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":null,"securityClass":"Common Stock par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"ARCH Venture Partners XIII, LLC","reportingCik":null,"personType":"OO","sharesOwned":2759072,"percentOfClass":13,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001012975-25-000768","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":null,"securityClass":"Common Stock par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Keith Crandell","reportingCik":null,"personType":"IN","sharesOwned":2759072,"percentOfClass":13,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001012975-25-000768","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":null,"securityClass":"Common Stock par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Robert Nelsen","reportingCik":null,"personType":"IN","sharesOwned":2759072,"percentOfClass":13,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001012975-25-000768","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":null,"securityClass":"Common Stock par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Steven Gillis","reportingCik":null,"personType":"IN","sharesOwned":2759072,"percentOfClass":13,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001012975-25-000768","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":null,"securityClass":"Common Stock par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Kristina Burow","reportingCik":null,"personType":"IN","sharesOwned":2759072,"percentOfClass":13,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001012975-25-000768","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":null,"securityClass":"Common Stock par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"ARCH Venture Fund IX, L.P.","reportingCik":null,"personType":"PN","sharesOwned":2759072,"percentOfClass":13,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001012975-25-000768","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":null,"securityClass":"Common Stock par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"ARCH Venture Fund IX Overage, L.P.","reportingCik":null,"personType":"PN","sharesOwned":2759072,"percentOfClass":13,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001012975-25-000768","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":null,"securityClass":"Common Stock par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Clinton Bybee","reportingCik":null,"personType":"IN","sharesOwned":1820634,"percentOfClass":8.6,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001104659-25-112479","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":null,"securityClass":"Common Stock, par value $0.0001","eventDate":"2025-09-30","reportingPerson":"James B. Tananbaum","reportingCik":null,"personType":"IN","sharesOwned":1454616,"percentOfClass":7.6,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001012975-25-000768","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":null,"securityClass":"Common Stock par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Paul Berns","reportingCik":null,"personType":"IN","sharesOwned":938438,"percentOfClass":4.4,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001104659-25-112479","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":null,"securityClass":"Common Stock, par value $0.0001","eventDate":"2025-09-30","reportingPerson":"Foresite Capital Management IV, LLC","reportingCik":null,"personType":"OO","sharesOwned":800339,"percentOfClass":4.2,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001104659-25-112479","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":null,"securityClass":"Common Stock, par value $0.0001","eventDate":"2025-09-30","reportingPerson":"Foresite Capital Fund IV, L.P.","reportingCik":null,"personType":"PN","sharesOwned":800339,"percentOfClass":4.2,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001104659-25-112479","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":null,"securityClass":"Common Stock, par value $0.0001","eventDate":"2025-09-30","reportingPerson":"Foresite Capital Fund V, L.P.","reportingCik":null,"personType":"PN","sharesOwned":477078,"percentOfClass":2.5,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001104659-25-112479","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":null,"securityClass":"Common Stock, par value $0.0001","eventDate":"2025-09-30","reportingPerson":"Foresite Capital Management V, LLC","reportingCik":null,"personType":"OO","sharesOwned":477078,"percentOfClass":2.5,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001104659-25-112479","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":null,"securityClass":"Common Stock, par value $0.0001","eventDate":"2025-09-30","reportingPerson":"Foresite Capital Opportunity Fund V, L.P.","reportingCik":null,"personType":"PN","sharesOwned":177199,"percentOfClass":0.9,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001104659-25-112479","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":null,"securityClass":"Common Stock, par value $0.0001","eventDate":"2025-09-30","reportingPerson":"Foresite Capital Opportunity Management V, LLC","reportingCik":null,"personType":"OO","sharesOwned":177199,"percentOfClass":0.9,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001140361-25-042006","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001806952","issuerName":"Lyell Immunopharma, Inc.","ticker":"LYEL","cusip":null,"securityClass":"Common Stock, par value $0.0001","eventDate":"2025-11-06","reportingPerson":"Innovative Cellular Therapeutics Holdings Ltd","reportingCik":null,"personType":"OO","sharesOwned":1900000,"percentOfClass":9.8,"filedAt":"2025-11-13","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001193125-25-277861","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001806952","issuerName":"LYELL IMMUNOPHARMA, INC.","ticker":"LYEL","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-09-30","reportingPerson":"Newton (PTC) Limited","reportingCik":null,"personType":"CO","sharesOwned":754698,"percentOfClass":3.93,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001193125-25-277861","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001806952","issuerName":"LYELL IMMUNOPHARMA, INC.","ticker":"LYEL","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-09-30","reportingPerson":"Orland Properties Limited","reportingCik":null,"personType":"CO","sharesOwned":754698,"percentOfClass":3.93,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001193125-25-277861","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001806952","issuerName":"LYELL IMMUNOPHARMA, INC.","ticker":"LYEL","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-09-30","reportingPerson":"Gemini GP Limited","reportingCik":null,"personType":"CO","sharesOwned":754698,"percentOfClass":3.93,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"},{"accessionNo":"0001193125-25-277861","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001806952","issuerName":"LYELL IMMUNOPHARMA, INC.","ticker":"LYEL","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-09-30","reportingPerson":"Gemini Investments, L.P.","reportingCik":null,"personType":"PN","sharesOwned":754698,"percentOfClass":3.93,"filedAt":"2025-11-12","canonicalUrl":"https://xoomar.com/markets/stocks/lyel"}],"updatedAt":"2026-11-04T01:35:27.547Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/lyel","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}